EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price

Alyssa K Amick, G Ege Eskibozkurt, Sybil G Hosek, Clare F Flanagan, Raphael J Landovitz, Elena Y Jin, Craig M Wilson, Kenneth A Freedberg, Milton C Weinstein, Pooyan Kazemian, A David Paltiel, Andrea L Ciaranello und 1 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciad566 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Alyssa K Amick und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, Pre-Exposure Prophylaxis, Sexual and Gender Minorities, HIV Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, NICHD NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adherence and retention concerns raise questions about the effectiveness and cost-effectiveness of oral HIV pre-exposure prophylaxis (PrEP) in young men who have sex with men (YMSM).

Methods

Using an adolescent-focused simulation model, we compared annual HIV screening alone with tenofovir disoproxil fumarate/emtricitabine–based oral PrEP with every 3-month HIV screening in YMSM (aged 15–24) at increased risk of HIV. Data derived from published sources included: age-stratified HIV incidence/100 person-years (PY) on- or off-PrEP (0.6–10.1 or 0.4–6.4), PrEP retention at 6 years (28%), transmissions by HIV RNA level (0.0–78.4/100PY) and annual costs of antiretroviral therapy ($32 000–69 000), HIV care ($3100–34 600), and PrEP program/generic drug ($900/360). Outcomes included transmissions (percent of cohort infected), quality-adjusted life-years (QALYs), costs ($), and incremental cost-effectiveness ratios ($/QALY). We explored the sensitivity of findings to variation in HIV incidence and drug prices.

Results

Compared with annual screening alone, PrEP would increase QALYs (9.58 to 9.67), reduce new infections (37% to 30%), and decrease costs (by $5000) over 10 years. PrEP would remain cost-saving for HIV incidence off-PrEP ≥5.1/100PY or annual PrEP price ≤$1200. Over a lifetime horizon, PrEP would be cost-saving for HIV incidence off-PrEP ≥1.0/100PY, across all retention assumptions examined. PrEP would not be cost-effective at HIV incidence ≤0.1/100PY, regardless of drug price, due to programmatic costs.

Conclusions

In US YMSM at increased risk of HIV, generic oral PrEP and every-3-month screening would be cost-saving compared with annual screening alone, even with high discontinuation and low adherence, over a range of HIV incidences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsPre-Exposure ProphylaxisSexual and Gender MinoritiesHIV InfectionsMaleAdolescentHumansUnited StatesHomosexuality, MaleDrugs, GenericCost-Benefit Analysis

Stichwörter der Autor:innen

HIVYMSMcost-effectivenesspre-exposure prophylaxisyouth

Substanzen

Anti-HIV AgentsDrugs, Generic

Autor:innen und Institutionen

  • Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Stroger Hospital of Cook County, Chicago, Illinois, USA.
  • UCLA Center for Clinical AIDS Research & Education, Los Angeles, California, USA.
  • Department of Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, Alabama, USA.
  • Division of Infectious Diseases, Department of Medicine; Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Anne M Neilan

Förderung

  • NIDA NIH HHS
  • NICHD NIH HHS
  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • National Institute on Drug Abuse
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Amick, A. K., Eskibozkurt, G. E., Hosek, S. G., Flanagan, C. F., Landovitz, R. J., Jin, E. Y., Wilson, C. M., Freedberg, K. A., Weinstein, M. C., Kazemian, P., Paltiel, A. D., Ciaranello, A. L., & Neilan, A. M. (2024). Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad566

Vancouver

Amick AK, Eskibozkurt GE, Hosek SG, Flanagan CF, Landovitz RJ, Jin EY, et al. Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad566

BibTeX
@article{Amick2024,
  author = {Amick, Alyssa K and Eskibozkurt, G Ege and Hosek, Sybil G and Flanagan, Clare F and Landovitz, Raphael J and Jin, Elena Y and Wilson, Craig M and Freedberg, Kenneth A and Weinstein, Milton C and Kazemian, Pooyan and Paltiel, A David and Ciaranello, Andrea L and Neilan, Anne M},
  title = {Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciad566}
}
Kostenlos starten →